| 1 |
Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines
Clotilde Théry et al. · Journal of Extracellular Vesicles
Open access382 authors |
23 Nov 2018 |
11,535 |
| 2 |
A roadmap for graphene
Kostya S. Novoselov, Vladimir I. Fal’ko, Luigi Colombo et al. · Nature
|
Oct 2012 |
9,276 |
| 3 |
A comparison of normalization methods for high density oligonucleotide array data based on variance and bias
Benjamin M. Bolstad, Rafael A. Irizarry, Magnus Åstrand et al. · Bioinformatics
Open access |
21 Jan 2003 |
8,511 |
| 4 |
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Tony S.K. Mok, Yi-Long Lung Cancer Wu, Sumitra Thongprasert et al. · New England Journal of Medicine
Open access |
19 Aug 2009 |
8,331 |
| 5 |
Fluorine in medicinal chemistry
Sophie Purser, Peter R. Moore, Steve Swallow et al. · Chemical Society Reviews
Review |
13 Dec 2007 |
7,580 |
| 6 |
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
Lars C. Wallentin, Richard C. Becker, Andrzej Budaj et al. · New England Journal of Medicine
Open access |
30 Aug 2009 |
7,154 |
| 7 |
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Stephen D. Wiviott, Itamar Raz, Marc P. Bonaca et al. · New England Journal of Medicine
Open access |
10 Nov 2018 |
6,466 |
| 8 |
The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research
Nathalie Percie du Sert et al. · PLoS Biology
Open access |
14 Jul 2020 |
6,005 |
| 9 |
Dapagliflozin in Patients with Chronic Kidney Disease
Hiddo J.L. Heerspink, Bergur V. Stefánsson, Ricardo Correa‐Rotter et al. · New England Journal of Medicine
Open access |
24 Sep 2020 |
5,523 |
| 10 |
The Microbial Metabolites, Short-Chain Fatty Acids, Regulate Colonic T reg Cell Homeostasis
Patrick M. Smith, Michael R. Howitt, Nicolai S. Panikov et al. · Science
Open access |
5 Jul 2013 |
5,478 |
| 11 |
Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Jean‐Charles Soria et al. · New England Journal of Medicine
Open access |
18 Nov 2017 |
5,475 |
| 12 |
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
Merryn Voysey et al. · The Lancet
Open access765 authors |
8 Dec 2020 |
5,030 |
| 13 |
Drug repurposing: progress, challenges and recommendations
Sudeep P. Pushpakom, Francesco Iorio, Patrick A. Eyers et al. · Nature Reviews Drug Discovery
Review |
12 Oct 2018 |
4,863 |
| 14 |
Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches
Joshua A Welsh et al. · Journal of Extracellular Vesicles
Open access |
Feb 2024 |
4,377 |
| 15 |
FinnGen provides genetic insights from a well-phenotyped isolated population
Mitja Kurki et al. · Nature
Open access169 authors |
18 Jan 2023 |
4,362 |
| 16 |
Core outcome measures for chronic pain clinical trials: IMMPACT recommendations
Robert H. Dworkin et al. · Pain
|
6 Nov 2004 |
3,789 |
| 17 |
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Peter C.C. Fong, David S. Boss, Timothy Anthony Yap et al. · New England Journal of Medicine
Open access |
24 Jun 2009 |
3,663 |
| 18 |
Core outcome domains for chronic pain clinical trials: IMMPACT recommendations
Dennis C. Turk et al. · Pain
|
22 Sep 2003 |
3,518 |
| 19 |
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Benjamin M. Scirica, Deepak L. Bhatt, Eugene Braunwald et al. · New England Journal of Medicine
Open access |
2 Sep 2013 |
3,507 |
| 20 |
Interpreting the Clinical Importance of Treatment Outcomes in Chronic Pain Clinical Trials: IMMPACT Recommendations
Robert H. Dworkin et al. · Journal of Pain
Open access |
13 Dec 2007 |
3,496 |
| 21 |
Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity
John O’Brien, Ian D. Wilson, Terry C. Orton et al. · European Journal of Biochemistry
Open access |
Sep 2000 |
3,452 |
| 22 |
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
Tony S.K. Mok, Yi-Long Lung Cancer Wu, Myung‐Ju Ahn et al. · New England Journal of Medicine
Open access |
6 Dec 2016 |
3,396 |
| 23 |
Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry
Warwick B. Dunn, David Broadhurst, Paul Begley et al. · Nature Protocols
|
30 Jun 2011 |
3,360 |
| 24 |
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark E. Robson, Seock‐Ah Im, Elżbieta Senkus et al. · New England Journal of Medicine
Open access |
4 Jun 2017 |
3,322 |
| 25 |
Clinical Practice Guidelines for the Management Candidiasis: 2009 Update by the Infectious Diseases Society of America
Peter G. Pappas, Carol A. Kauffman, David R. Andes et al. · Clinical Infectious Diseases
Open access |
29 Jan 2009 |
3,216 |
| 26 |
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial
Salim Yusuf, Marc Alan Pfeffer, Karl B Swedberg et al. · The Lancet
|
Sep 2003 |
3,011 |
| 27 |
Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC
Suresh S. Ramalingam et al. · New England Journal of Medicine
Open access |
21 Nov 2019 |
2,933 |
| 28 |
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Kathleen N. Moore et al. · New England Journal of Medicine
Open access |
21 Oct 2018 |
2,927 |
| 29 |
Pericytes regulate the blood–brain barrier
Annika Armulik, Guillem Genové, Maarja Andaloussi Mäe et al. · Nature
Open access |
13 Oct 2010 |
2,915 |
| 30 |
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
Masahiro Fukuoka, Seiji Yano, Giuseppe Giaccone et al. · Journal of Clinical Oncology
|
20 May 2003 |
2,899 |
| 31 |
Reporting animal research: Explanation and elaboration for the ARRIVE guidelines 2.0
Nathalie Percie du Sert et al. · PLoS Biology
Open access |
14 Jul 2020 |
2,875 |
| 32 |
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Scott David Solomon et al. · New England Journal of Medicine
Open access |
27 Aug 2022 |
2,863 |
| 33 |
A view on drug resistance in cancer
Neil Vasan, José Baselga, David Michael Hyman · Nature
Open access |
13 Nov 2019 |
2,824 |
| 34 |
Premature ageing in mice expressing defective mitochondrial DNA polymerase
Aleksandra Trifunović, Anna Wredenberg, Maria Falkenberg et al. · Nature
|
May 2004 |
2,779 |
| 35 |
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition) 1
Daniel J. Klionsky et al. · Autophagy
Open access2,930 authors |
2 Jan 2021 |
2,743 |
| 36 |
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial
John J.V. McMurray, Jan Östergren, Karl B Swedberg et al. · The Lancet
|
Sep 2003 |
2,612 |
| 37 |
New insights into the genetic etiology of Alzheimer’s disease and related dementias
Céline Bellenguez et al. · Nature Genetics
Open access1,266 authors |
Apr 2022 |
2,608 |
| 38 |
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer
Mark G. Kris, Ronald B. Natale, Roy S. Herbst et al. · JAMA
|
22 Oct 2003 |
2,547 |
| 39 |
The human tumor microbiome is composed of tumor type–specific intracellular bacteria
Deborah Nejman et al. · Science
Open access |
28 May 2020 |
2,523 |
| 40 |
Diagnosis and Management of Childhood Obstructive Sleep Apnea Syndrome
Carole L. Marcus, Lee J. Brooks, Kari A. Draper et al. · PEDIATRICS
|
27 Aug 2012 |
2,431 |
| 41 |
Quantifying the chemical beauty of drugs
G. Richard Bickerton, Gaia Valeria Paolini, Jérémy Besnard et al. · Nature Chemistry
Open access |
24 Jan 2012 |
2,382 |
| 42 |
The influence of drug-like concepts on decision-making in medicinal chemistry
Paul D. Leeson, Brian Springthorpe · Nature Reviews Drug Discovery
Review |
31 Oct 2007 |
2,354 |
| 43 |
Gut Microbiota Regulates Bile Acid Metabolism by Reducing the Levels of Tauro-beta-muricholic Acid, a Naturally Occurring FXR Antagonist
Sama I. Sayin, Annika M. Wahlstrom, Jenny Felin et al. · Cell Metabolism
Open access |
Feb 2013 |
2,351 |
| 44 |
Olaparib for Metastatic Castration-Resistant Prostate Cancer
Johann Sebastian De Bono, Joaquı́n Mateo, Karim S. Fizazi et al. · New England Journal of Medicine
Open access |
28 Apr 2020 |
2,322 |
| 45 |
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
Luis G Paz-Ares et al. · The Lancet
246 authors |
4 Oct 2019 |
2,310 |
| 46 |
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
M. William Audeh, James Carmichael, Richard T. Penson et al. · The Lancet
|
Jul 2010 |
2,298 |
| 47 |
AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
Darren A.E. Cross et al. · Cancer Discovery
Open access |
4 Jun 2014 |
2,276 |
| 48 |
Molecular Analysis of Commensal Host-Microbial Relationships in the Intestine
Lora V. Hooper, Melissa Hirose Wong, Anders G Thelin et al. · Science
|
2 Feb 2001 |
2,232 |
| 49 |
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
Rury R. Holman, Mary Angelyn Bethel, Robert John Mentz et al. · New England Journal of Medicine
Open access |
14 Sep 2017 |
2,195 |
| 50 |
What is meant by intention to treat analysis? Survey of published randomised controlled trials
S. Hollis, Fiona Campbell · BMJ
Open access |
11 Sep 1999 |
2,188 |